Histopathologic risk factors for progression of atypical meningioma: a retrospective cohort study evaluating the impact and clinical value of mitotic count and Ki-67
Acta Neurochirurgica · 2025
DOI: 10.1007/s00701-025-06711-4 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Acta Neurochirurgica, 2025. Verfasst von Yoon Hwan Byun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Meningioma, Ki-67 Antigen, Meningeal Neoplasms, Mitotic Index. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seoul National University.
Abstract (Originalsprache)
Purpose
Given the heterogeneity of atypical meningioma (AM) and potential interobserver variability in WHO grade assignment among pathologists, there is a need for more objective criteria to improve risk stratification. This study examined conventional and novel risk factors for AM progression, focusing on mitotic count (MC) and Ki-67, and explored their clinical relevance.
Methods
This retrospective cohort study included 240 consecutive patients with AM surgically treated at a single tertiary institution between 2001 and 2020. The cut-off values for MC and Ki-67 were determined using the Youden index. Risk factors for progression were analyzed using cause-specific Cox proportional hazards models. Progression-free survival (PFS) was estimated using cumulative incidence function (CIF) and compared using the Gray’s test.
Results
AM progression occurred in 32.5% of patients with a median time to progression of 25.2 months. The median follow-up was 42.3 months. While a clinically meaningful Ki-67 cut-off was not identified, MC ≥ 6 was significantly associated with AM progression. On multivariate analysis, age, gross total resection (GTR), MC ≥ 6, brain invasion, sheeting, and adjuvant radiotherapy (RTx) were associated with progression. RTx improved PFS in the subtotal resection (STR) group but not in the GTR group. Among GTR patients, those with MC ≥ 6 had worse outcomes.
Conclusion
GTR and RTx may reduce the progression of AM. MC ≥ 6 significantly increases the risk of progression, even in GTR patients. RTx should be considered for all STR patients A more vigilant follow-up or consideration of RTx is warranted in GTR patients when a high MC is identified.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea.
- Department of Neurosurgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
- Medical Research Collaborating Center, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea.
- Department of Neurosurgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea. ns.kimms@snu.ac.kr.
Förderung
- Seoul National University
Zitieren
APA
Byun, Y. H., Han, M., Nam, S. M., Hwang, J. H., Kim, Y. H., Park, C. K., & Kim, M. S. (2025). Histopathologic risk factors for progression of atypical meningioma: a retrospective cohort study evaluating the impact and clinical value of mitotic count and Ki-67. Acta Neurochirurgica. https://doi.org/10.1007/s00701-025-06711-4
Vancouver
Byun YH, Han M, Nam SM, Hwang JH, Kim YH, Park CK, et al. Histopathologic risk factors for progression of atypical meningioma: a retrospective cohort study evaluating the impact and clinical value of mitotic count and Ki-67. Acta Neurochirurgica. 2025. doi:10.1007/s00701-025-06711-4
BibTeX
@article{Byun2025,
author = {Byun, Yoon Hwan and Han, Mira and Nam, Sun Mo and Hwang, Jong Ha and Kim, Yong Hwy and Park, Chul-Kee and Kim, Min-Sung},
title = {Histopathologic risk factors for progression of atypical meningioma: a retrospective cohort study evaluating the impact and clinical value of mitotic count and Ki-67},
journal = {Acta Neurochirurgica},
year = {2025},
doi = {10.1007/s00701-025-06711-4}
}
EUVIMED